Franklin Resources Inc. Has $168.20 Million Stock Position in Medpace Holdings, Inc. $MEDP

Franklin Resources Inc. increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 158.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 299,472 shares of the company’s stock after purchasing an additional 183,645 shares during the quarter. Franklin Resources Inc.’s holdings in Medpace were worth $168,198,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Optiver Holding B.V. acquired a new stake in Medpace in the third quarter worth about $27,000. Steigerwald Gordon & Koch Inc. acquired a new stake in Medpace in the fourth quarter worth about $30,000. Elyxium Wealth LLC acquired a new stake in Medpace in the fourth quarter worth about $30,000. Quarry LP acquired a new stake in Medpace in the third quarter worth about $35,000. Finally, Core Wealth Advisors LLC acquired a new stake in Medpace in the fourth quarter worth about $47,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Truist Financial lowered their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. Barclays lowered their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Royal Bank Of Canada reduced their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Mizuho set a $582.00 target price on Medpace in a report on Wednesday, February 11th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday, February 13th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $467.08.

Medpace Trading Up 1.9%

Shares of MEDP opened at $466.79 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92. The stock has a market cap of $13.33 billion, a P/E ratio of 29.34, a price-to-earnings-growth ratio of 2.32 and a beta of 1.18. The stock’s 50-day moving average price is $456.86 and its two-hundred day moving average price is $506.57.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the business earned $3.67 earnings per share. The company’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Transactions at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.